Jun 18, 2020
RINVOQ(TM) (upadacitinib) Monotherapy Shows Improvement in Skin Clearance and Itch in First Phase 3 Study for Atopic Dermatitis
May 26, 2020
Arena Completes Full Enrollment of Etrasimod Phase 2 ADVISE Trial for Atopic Dermatitis, Provides Program Updates
Oct 28, 2019
Arena Pharmaceuticals Announces First Subject Dosed in ADVISE Phase 2 Trial Evaluating Etrasimod in Atopic Dermatitis
Oct 03, 2018
DS Biopharma Announces Positive Top-line Phase 2b Trial Results for Ds107 As a Topical Treatment for Mild to Moderate Atopic Dermatitis
Sep 13, 2018
AbbVie Presents Upadacitinib Longer-Term (32-Week) and Patient-Reported Outcomes Data from Phase 2b Atopic Dermatitis Study at 27th European Academy of Dermatology and Venereology (EADV) Congress
Jul 10, 2018
Realm Therapeutics Announces Publication of Pre-Clinical Study Demonstrating Comparable Activity of PR022 and Topical Tofacitinib in the Treatment of Atopic Dermatitis
May 24, 2018
Realm Therapeutics Completes Enrollment in Phase 2 Study of PR022 for Atopic Dermatitis
May 17, 2018
Glenmark Pharmaceuticals Announces Oral Presentation of New Data on GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at the International Investigative Dermatology Meeting
Apr 16, 2018
Glenmark Pharmaceuticals Announces Initiation of a Phase 2b Trial of GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis
Feb 17, 2018
AbbVie Presents New Late-Breaking Phase 2b Data on Upadacitinib in Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting
Feb 16, 2018
Glenmark Pharmaceuticals Presents New Data on GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting
Feb 15, 2018
Realm Therapeutics Highlights Strong 2017 Performance and Outlines 2018 Milestones
Dec 05, 2017
Realm Therapeutics Announces First Patient Dosed in Phase 2 Study of PR022 for the Treatment of Atopic Dermatitis
Dec 04, 2017
Health Canada approves Dupixent(TM), the first targeted treatment for adults with moderate-to-severe atopic dermatitis
Sep 07, 2017
AbbVie's Upadacitinib (ABT-494) Meets Primary Endpoint in Phase 2b Study in Atopic Dermatitis
Sep 06, 2017
Medimetriks Announces Phase 2 Study Results Demonstrating Early Itch Relief for Topical PDE4 Inhibitor MM36 in Patients with Atopic Dermatitis
Jul 31, 2017
Glenmark Pharmaceuticals Reports Positive Data in a Phase 2a Study of GBR 830 for the Treatment of Patients with Atopic Dermatitis